Loading
KP
Kiniksa Pharmaceuticals International, plc Stock: price and insider trades · United States
Kiniksa Pharmaceuticals International, plc: what insiders have been doing
Kiniksa Pharmaceuticals International, plc is a listed company. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 106 filings signed by 12 insiders.
There is no open-market purchase to report; the filings show 16 sales worth €16.6M by 6 insiders. No amount is published for 1 filing, which the totals therefore leave out. One trade stands out by size: a sale of €5.0M from Patel Sanj K, disclosed on 30 April 2026.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 106 filings, this issuer sits above that mark. Our records for Kiniksa Pharmaceuticals International, plc go back to 2022, with no purchases and 23 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 677.6 m USD of revenue and 59.0 m USD of net income.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
287
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€21M
23 ops. · all time
Who traded when
BuySaleSanj K. Patel11 sales
Ross Moat4 sales
Barry D. Quart2 sales
Michael R. Megna2 sales
G. Bradley Cole1 sale
Mark Ragosa1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 3 September 2026
Declarations287 total
3,932 sharesClass A Ordinary ShareSEC:0001464583-26-000008:1
2,558 sharesClass A Ordinary ShareSEC:0001464583-26-000008:2
2,362 sharesClass A Ordinary ShareSEC:0001464583-26-000008:3
9,991 sharesClass A Ordinary ShareSEC:0001532218-26-000014:0
6,481 sharesClass A Ordinary ShareSEC:0001532218-26-000014:1
8,609 sharesClass A Ordinary ShareSEC:0001532218-26-000014:3
9,991 sharesClass A Ordinary ShareSEC:0001532218-26-000016:0
6,481 sharesClass A Ordinary ShareSEC:0001532218-26-000016:1
6,237 sharesClass A Ordinary ShareSEC:0001532218-26-000016:2
8,609 sharesClass A Ordinary ShareSEC:0001532218-26-000016:3
1,750 sharesClass A Ordinary ShareSEC:0001741533-26-000010:2
2,457 sharesClass A Ordinary ShareSEC:0001741533-26-000010:3
2,694 sharesClass A Ordinary ShareSEC:0001835458-26-000012:0
3,069 sharesClass A Ordinary ShareSEC:0001835458-26-000012:3
279 shares@ US$33.500.0000% mcap0.5% of flowClass A Ordinary ShareSEC:0001464583-26-000008:0
5,531 shares@ US$79.280.0001% mcap23.5% of flowClass A Ordinary ShareSEC:0001464583-26-000008:5
4,600 shares@ US$80.300.0001% mcap19.8% of flowClass A Ordinary ShareSEC:0001464583-26-000008:6
15,144 shares@ US$79.280.0004% mcap4.0% of flowClass A Ordinary ShareSEC:0001532218-26-000014:4
4,029 shares@ US$79.280.0001% mcap26.2% of flowClass A Ordinary ShareSEC:0001741533-26-000010:4
4,404 shares@ US$79.280.0001% mcap8.4% of flowClass A Ordinary ShareSEC:0001835458-26-000012:4
25 of 287 declarations
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. It is listed on NASDAQ under the ticker KNSA.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
